Genfit S.A. (XUP)
Market Closed
7 Aug, 20:00
€
13. 98
+0.36
+2.6432%
€
- Market Cap
- P/E Ratio
- Div Yield
0 Volume
- Eps
€ 13.62
Previous Close Want to track XUP and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
XUP closed Friday higher at €13.98, an increase of 2.6432% from Thursday's close, completing a monthly increase of 32.8897% or €3.46. Over the past 12 months, XUP stock gained 165.0237%.
XUP is not paying dividends to its shareholders.
The last earnings report, released on Apr 02, 2026, exceeded the consensus estimates by 0.35%. On average, the company has surpassed earnings expectations by 0.08%, based on the last three reports.
Genfit S.A. has completed 2 stock splits, with the recent split occurring on Oct 12, 2016.
The company's stock is traded on 8 different exchanges and in various currencies, with the primary listing on XPAR (EUR).
XUP Chart
Genfit S.A. (XUP) FAQ
What is the stock price today?
The current price is €13.98.
On which exchange is it traded?
Genfit S.A. is listed on XDUS.
What is its stock symbol?
The ticker symbol is XUP.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Genfit S.A. ever had a stock split?
Genfit S.A. had 2 splits and the recent split was on Oct 12, 2016.
Genfit S.A. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Jean-Francois Mouney CEO | XDUS Exchange | FR0004163111 ISIN |
| FR Country | 188 Employees | - Last Dividend | 12 Oct 2016 Last Split | - IPO Date |
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.
Contact Information
Address: Parc EurasantE, Loos, France, 59120
Phone: 33 3 20 16 40 00
Website: https://www.genfit.com
